Medications and Substances Delivered by Iontophoresis: Evidence and Polarity Guide
Iontophoresis uses a low-level direct electrical current to increase the movement of ionic or polar substances across the skin. In simplified terms, a positively charged substance is placed beneath the positive electrode, while a negatively charged substance is placed beneath the negative electrode.
The actual process is more complex than “like charges repel.” Drug movement can also be affected by electro-osmosis, changes in skin permeability, molecular size, concentration, competing ions, treatment duration, electrode design, skin resistance, and the chemical form of the substance.
This guide reviews substances that have been reported in clinical, diagnostic, historical, or experimental iontophoresis literature. It is an educational index—not a medication order, treatment protocol, or statement that every substance is appropriate for current clinical use.
Important: The appearance of a substance in published literature does not establish that it is effective, FDA-approved for iontophoretic administration, compatible with a particular electrode or patch, or appropriate for an individual patient. Always follow the prescription, pharmacy instructions, product labeling and device Instructions for Use.
For general information about dose, current, and electrode placement, visit our Iontophoresis Frequently Asked Questions.
Iontophoresis Substances at a Glance
| Substance or solution | Commonly reported charge | Principal literature application | Evidence summary |
|---|---|---|---|
| Dexamethasone sodium phosphate | Negative | Selected inflammatory musculoskeletal conditions and tendinopathies | Condition-specific clinical evidence; outcomes vary |
| Acetic acid or acetate | Negative | Calcific tendinopathy and plantar heel pain | Limited and mixed clinical evidence |
| Lidocaine hydrochloride | Positive | Local dermal anesthesia | Supported by multiple controlled studies |
| Pilocarpine | Positive | Sweat induction for cystic-fibrosis testing | Established diagnostic application |
| Tap water | Both polarities are typically alternated | Palmar and plantar hyperhidrosis | Established dermatologic application |
| Glycopyrrolate or glycopyrronium | Positive | Hyperhidrosis | Reported in smaller and older studies |
| Sodium salicylate | Negative | Pain and inflammatory conditions | Limited older clinical literature |
| Sodium diclofenac | Negative | Lateral elbow pain | Limited small-study evidence |
| Hyaluronidase | Formulation-dependent | Historically investigated for edema and tissue permeability | Limited or historical reports |
| Magnesium, calcium, iodide, zinc and other ions | Ion-dependent | Varied historical physical-medicine and dermatologic purposes | Predominantly historical or low-level evidence |
| Vincristine or vinblastine | Positive in older reports | Historical investigations of severe neuralgia | Hazardous cytotoxic drugs; not routine rehabilitation use |
The strongest evidence and clearest accepted uses do not necessarily involve the same clinical specialty. Pilocarpine iontophoresis is established in diagnostic sweat testing; lidocaine has controlled evidence for local anesthesia; and tap-water iontophoresis is recognized in hyperhidrosis care. Rehabilitation uses such as dexamethasone or acetic acid tend to have more condition-specific and mixed results. (Cystic Fibrosis Foundation)
How to Interpret the Evidence
This article uses four general evidence categories.
| Evidence category | Meaning |
|---|---|
| Established application | Supported by clinical guidance, standardized diagnostic practice or multiple controlled studies |
| Condition-specific evidence | Supported for a defined condition, but not necessarily generalizable to other diagnoses |
| Limited evidence | Small studies, inconsistent findings, case reports or older trials |
| Historical or experimental | Reported in older publications, laboratory research, specialty drug-device development or isolated clinical reports |
A study demonstrating that a substance entered the skin or was detected in underlying tissue does not prove that the treatment improved pain, healing, or function. Pharmacokinetic transport and clinical effectiveness are separate research questions.
Why Salt Form and Polarity Matter
Medication names alone are not sufficient for selecting electrode polarity. The full formulation matters.
For example:
- Dexamethasone sodium phosphate is generally treated as a negatively charged phosphate formulation.
- Lidocaine hydrochloride is commonly delivered as a positively charged ion.
- Acetic acid produces negatively charged acetate ions in solution.
- Pilocarpine salts are commonly delivered from the positive electrode.
- Potassium iodide contains positively charged potassium and negatively charged iodide ions; the intended therapeutic ion must be identified.
Polarity can be influenced by:
- The particular salt form
- Solution pH
- Concentration
- Buffering agents
- Preservatives
- Competing ions
- The medication vehicle
- The product’s specific Instructions for Use
Before connecting an iontophoresis electrode, consult the prescription, dispensing pharmacy, and product labeling. Our Iontophoresis Electrode Directions for Use provides additional guidance on electrode connections and polarity.
Dexamethasone Sodium Phosphate Iontophoresis
Dexamethasone sodium phosphate is one of the most frequently discussed iontophoresis medications in physical therapy, sports medicine, and rehabilitation literature.
| Dexamethasone consideration | Literature summary |
|---|---|
| Common formulation described | Approximately 0.4%, equivalent to 4 mg/mL |
| Commonly reported polarity | Negative |
| Drug class | Corticosteroid |
| Reported clinical areas | Achilles tendinopathy, lateral epicondylitis, plantar heel pain, carpal tunnel syndrome and other inflammatory presentations |
| Evidence | Varies considerably by diagnosis and study design |
| Main caution | A reported anti-inflammatory rationale does not establish benefit for every tendinopathy |
Human studies have confirmed that treatment conditions such as current magnitude, treatment duration, competing ions, and skin thickness influence dexamethasone-phosphate transport. Clinical results, however, have not been uniformly positive. (PubMed)
Achilles tendinopathy
The 2024 Academy of Orthopaedic Physical Therapy clinical practice guideline retains a grade-B recommendation that clinicians use dexamethasone iontophoresis to decrease pain and improve function in acute midportion Achilles tendinopathy. The recommendation is diagnosis- and stage-specific; it should not be generalized to every Achilles disorder or chronic tendon presentation. (APTA Orthopedics)
Lateral epicondylitis
Clinical studies have reported short-term improvements after dexamethasone iontophoresis for lateral epicondylitis, including earlier improvement in grip strength or return to unrestricted work in some comparisons. These findings do not establish superior long-term outcomes over every other treatment. (Jhandsurg)
Balego also provides a summary of corticosteroid iontophoresis compared with injection for lateral epicondylitis.
Plantar heel pain
A small randomized trial compared 0.4% dexamethasone, 5% acetic acid, and saline placebo iontophoresis when all groups also received low-dye taping and stretching. The study supports describing these substances as investigated treatments, but its size and combined interventions limit broad conclusions. (PMC)
Acetic Acid Iontophoresis
Acetic acid has traditionally been discussed for conditions involving calcium deposits because acetate is a negatively charged ion. Common literature examples include 2% to 5% solutions, although the presence of a published concentration is not a recommendation to compound or administer it.
| Acetic-acid consideration | Literature summary |
|---|---|
| Reported active ion | Acetate |
| Commonly reported polarity | Negative |
| Frequently cited concentration | 5% in several musculoskeletal studies |
| Reported uses | Calcific tendinopathy and plantar heel pain |
| Evidence quality | Limited and inconsistent |
| Appropriate conclusion | Investigated in the literature, not proven to “dissolve” every calcium deposit |
Calcific shoulder tendinopathy
A double-blind randomized trial found that adding acetic-acid iontophoresis to physiotherapy did not produce better clinical or radiographic results than physiotherapy alone. Case reports and uncontrolled series have described improvement, but these lower-level reports cannot establish that acetic acid caused deposit resorption. (ScienceDirect)
This distinction is important for SEO and clinical accuracy. The page should not claim that acetic acid iontophoresis reliably “dissolves calcium,” “removes bone spurs," or reverses calcific tendinopathy.
Plantar fasciitis and heel pain
Acetic acid has also appeared in plantar fasciitis and heel pain literature. The available studies are generally small and frequently combine iontophoresis with taping, stretching, orthoses or other interventions. Results should therefore be described as preliminary or condition-specific rather than definitive. (PMC)
Lidocaine Iontophoresis
Lidocaine is a local anesthetic. Lidocaine hydrochloride is commonly described as positively charged for iontophoresis.
| Lidocaine consideration | Literature summary |
|---|---|
| Commonly reported polarity | Positive |
| Studied formulations | Frequently 2% or 4%, sometimes with epinephrine |
| Principal application | Local dermal anesthesia |
| Evidence | Multiple randomized and controlled studies |
| Important limitation | Anesthesia studies do not validate unrelated musculoskeletal uses |
Controlled studies have evaluated iontophoretic delivery of 2% lidocaine with epinephrine before intravenous cannulation and dermatologic procedures. Several reported reduced procedural pain or a reduced need for supplemental anesthetic compared with the placebo. (PubMed)
Other research has compared iontophoretic lidocaine with injection, topical application, and alternative enhanced-delivery methods. The depth, onset, and duration of anesthesia depend on the formulation and delivery conditions. (PubMed)
Lidocaine should not be added to a patch or electrode unless it has been specifically prescribed and the formulation is compatible with the selected drug-delivery system.
Pilocarpine Iontophoresis for Sweat Testing
Quantitative pilocarpine iontophoresis occupies a different category from rehabilitation drug delivery. It is a standardized method of stimulating sweat so that sweat chloride can be measured during evaluation for cystic fibrosis.
The Cystic Fibrosis Foundation states that quantitative pilocarpine iontophoresis remains the standard sweat-testing method for cystic fibrosis diagnosis. Collection, measurement, and interpretation require rigorously controlled laboratory procedures. (Cystic Fibrosis Foundation)
| Pilocarpine consideration | Literature summary |
|---|---|
| Reported polarity | Positive |
| Purpose | Sweat stimulation |
| Main application | Quantitative sweat-chloride testing |
| Status | Established diagnostic application |
| Appropriate setting | Qualified laboratory or accredited clinical program |
| Not equivalent to | Routine rehabilitation iontophoresis |
Pilocarpine sweat testing should not be attempted using ordinary physical-therapy electrodes or wearable medication patches.
Tap-Water Iontophoresis for Hyperhidrosis
Tap-water iontophoresis is used to reduce excessive sweating, particularly of the palms and soles. No prescription medication is necessarily added to the water; the treatment involves current passing through the water and the treated area.
Because both sides are treated and polarity may be alternated, tap-water iontophoresis does not fit neatly into a single medication-polarity chart.
| Tap-water consideration | Literature summary |
|---|---|
| Primary application | Palmar and plantar hyperhidrosis |
| Added prescription drug | Not necessarily |
| Polarity | Commonly alternated |
| Evidence | Recognized dermatologic application |
| Axillary use | Evidence and practicality are less consistent |
| Maintenance | Frequently required after initial response |
Clinical literature and dermatology reviews identify iontophoresis as an established option for localized hyperhidrosis. Evidence is strongest for palmar and plantar areas, while axillary results and device practicality are more variable. (JAAD)
Anticholinergic additives
Older and smaller studies have examined anticholinergic agents such as the following:
- Glycopyrrolate or glycopyrronium bromide
- Atropine sulfate
- Poldine methylsulfate
Some reports compared glycopyrrolate-enhanced treatment with tap water or combined an anticholinergic with aluminum chloride. These approaches carry medication-specific risks and should not be presented as routine home-water additives. (JAAD)
A recent randomized study also compared aluminum chloride hexahydrate gel iontophoresis with tap-water iontophoresis for palmar hyperhidrosis, illustrating that research in this area continues to evolve. (PubMed)
Salicylate and Diclofenac Iontophoresis
Sodium salicylate and sodium diclofenac have both appeared in musculoskeletal iontophoresis studies.
| Substance | Commonly reported charge | Reported application | Evidence status |
|---|---|---|---|
| Sodium salicylate | Negative | Painful or inflammatory musculoskeletal conditions | Limited older evidence |
| Sodium diclofenac | Negative | Lateral epicondylitis | Limited small-study evidence |
One randomized study assigned patients with lateral epicondylitis to sodium-diclofenac or sodium-salicylate iontophoresis. This demonstrates that both substances have been clinically investigated, but a small comparative study is not enough to establish either as a standard iontophoresis medication. (PubMed)
Medication-specific contraindications remain relevant even when a drug is administered through the skin.
Historical Substances Reported in Iontophoresis Literature
The following entries appear in older medical, dermatologic, or physical-medicine literature. Many rely on case reports, uncontrolled observations, or outdated formulations or product names that are no longer commonly used.
| Substance or historical term | Commonly reported ion or polarity | Historical purpose described | Current interpretation |
|---|---|---|---|
| Atropine sulfate | Positive | Hyperhidrosis | Historical anticholinergic use |
| Calcium chloride | Calcium ion: positive | Muscle spasm or impaired muscle function | Predominantly historical |
| Sodium chloride | Chloride ion: negative | Scar tissue or adhesions | Weak historical rationale |
| Potassium citrate | Citrate ion: negative | Rheumatic conditions | Historical and poorly supported |
| Copper sulfate | Copper ion: positive | Astringent or antifungal purposes | Historical |
| Gentamicin sulfate | Commonly treated as positive | Local antimicrobial delivery | Isolated specialty reports |
| Hyaluronidase | Formulation- and pH-dependent | Edema or enhancement of tissue permeability | Historical; not a general iontophoresis additive |
| Idoxuridine | Formulation-dependent | Herpes-simplex applications | Historical antiviral research |
| Iodide or potassium iodide | Iodide ion: negative | Scar tissue or fibrosis | Historical |
| Lithium chloride | Lithium ion: positive | Gouty arthritis | Historical |
| Magnesium sulfate | Magnesium ion: positive | Myalgia, spasm or vasodilation | Historical |
| Methacholine chloride or Mecholyl | Positive | Vasodilation | Obsolete therapeutic context |
| Methylprednisolone sodium succinate | Formulation-dependent | Inflammatory or neuralgic conditions | Limited specialty reports |
| Penicillin salts | Depends on specific salt and pH | Infected wounds or burns | Historical |
| Silver salts | Silver ion: positive | Infection or osteomyelitis | Historical |
| Zinc compounds | Zinc ion: positive | Ulcers, dermatitis or wound healing | Case-level and historical reports |
| Meladinine sodium salt | Reported as negative | Vitiligo with ultraviolet treatment | Historical terminology and protocol |
| Vincristine or vinblastine | Positive in the cited report | Severe post-herpetic or trigeminal neuralgia | Hazardous cytotoxic drugs; not routine use |
A 1982 report described iontophoretic administration of vincristine or vinblastine for chronic neuralgia. These are potent cytotoxic chemotherapy drugs, and the old report should be treated as medical history—not as a practical rehabilitation protocol. (PubMed)
Similarly, a 1969 publication reported iontophoresis of the sodium salt of “meladinine” for vitiligo. Modern readers should not assume that the historical name, formulation, or combined ultraviolet protocol corresponds to a currently available product. (PubMed)
Updating Obsolete Names in Older Iontophoresis Charts
Legacy charts often use trade names or terminology that can confuse modern readers.
| Older term | Modern interpretation |
|---|---|
| Mecholyl | Historical brand name associated with methacholine chloride |
| Wyadase or Wydase | Historical hyaluronidase preparation |
| Iodex | Proprietary topical iodine ointment rather than a standardized generic iontophoresis solution |
| Meladinine | Historical term associated with a khellin-related photosensitizing preparation used in vitiligo literature |
| “Iron/titanium oxide” | Insufficiently defined in many secondary charts; exact compound and formulation must be identified |
| “Water, positive or negative." | Usually refers to tap-water iontophoresis and electrode reversal, not drug delivery in the usual sense |
These names should not be copied into a modern medication order without identifying the exact active ingredient, concentration, charge, vehicle, and source publication.
Newer and Experimental Iontophoresis Research
Modern transdermal research extends beyond traditional rehabilitation medications.
| Substance or category | Research area | Present status |
|---|---|---|
| Dutasteride | Androgenetic alopecia | Emerging small clinical study |
| Tranexamic acid | Melasma | Small randomized dermatologic study |
| Botulinum toxin | Hyperhidrosis | Pilot and experimental delivery research |
| Insulin and peptide drugs | Systemic transdermal delivery | Primarily formulation and device research |
| Opioid analgesics | Specialized systemic drug-device systems | Not interchangeable with rehabilitation iontophoresis equipment |
| Diclofenac and other NSAIDs | Local musculoskeletal delivery | Human and preclinical research; formulation-specific |
| Nanoparticle-assisted drugs | Enhanced transdermal transport | Experimental |
A 2025 study reported preliminary results for dutasteride delivered with iontophoresis in treatment-resistant androgenetic alopecia, while a randomized study investigated tranexamic-acid essence with iontophoresis for melasma. These specialized dermatologic techniques should not be assumed compatible with physical-therapy electrodes or wearable rehabilitation patches. (PubMed)
Reviews of transdermal iontophoresis also discuss peptides, systemic analgesics, and other larger or less skin-permeable molecules. Much of this work depends on purpose-built formulations and drug-device combinations. (PubMed)
Clinical Evidence: Transport Does Not Equal Treatment Success
When reviewing an iontophoresis paper, ask what the investigators actually measured.
| Study outcome | What it establishes | What it does not establish |
|---|---|---|
| Drug detected beneath the skin | Some transdermal transport occurred | Symptoms or function improved |
| Higher tissue concentration | Delivery differed from a control | The concentration was clinically effective |
| Short-term pain reduction | Symptoms changed during the measured period | Long-term recovery or tissue healing |
| Smaller radiographic deposit | Imaging changed | Pain or function necessarily improved |
| Case-report success | Improvement occurred in one or several patients | The treatment caused the improvement |
| Laboratory skin model | Transport is physically possible | Safe or effective human use |
| Animal model | Biological activity may be plausible | Human efficacy or appropriate dosing |
| FDA device clearance | The delivery device met its cleared indication | Every drug-device combination is approved |
FDA documents describe iontophoresis devices generally as systems that use direct current to introduce ions of soluble salts or other drugs for medical purposes. The amount and distribution delivered can depend on charge, molecular weight, current, electrode composition, treatment duration and other variables. A device’s clearance does not independently validate every medication or formulation placed in it. (FDA Access Data)
Comparing Balego Iontophoresis Delivery Options
Selecting a medication is separate from selecting a delivery system. Dose capacity, polarity labeling, medication volume, and electrode design must all match the prescription and Instructions for Use.
| Delivery format | Balego option | Main characteristics | Best workflow fit |
|---|---|---|---|
| Self-contained wearable patch | IontoPATCH® STAT, 80 and Extra Strength | Built-in power source; 80 or 120 mA-min models; no external controller | Mobile, extended-wear treatment when the formulation and polarity are compatible |
| Self-contained no-saline patch | ACTIVApatch® IntelliDose, IontoGo 4.0 and IontoGo 12.0 | No added saline; current models are designed around negatively charged ionic solutions | Simplified preparation and multiple treatment-time options |
| Controller-based electrode kit | Ionto4™ Iontophoresis Electrodes | Drug and dispersive electrodes used with a compatible constant-current controller | Clinics requiring programmable current and treatment time |
| Buffered controller-based kit | Buffered Iontophoresis Electrode Kits | Ag/AgCl drug electrode and buffered return electrode | Professional controller-based treatments |
| Flexible electrode system | Trivarion™ Iontophoresis Delivery Kit | Form-fitting construction for curved or uneven areas | Sites where flat electrode contact is difficult |
Medication is not included with these products. Current specifications and polarity limitations should be checked before purchasing or applying any system.
For a detailed wearable-patch comparison, read IontoPatch vs. ACTIVApatch.
Browse our complete selection of iontophoresis patches, controllers, and electrode kits.
Medication and Device Compatibility Checklist
Before iontophoresis, confirm all of the following:
| Question | Why it matters |
|---|---|
| What is the exact medication name? | Similar names can represent different active compounds |
| What is the salt form? | Salt form can change polarity and transport |
| What is the prescribed concentration? | Literature concentrations are not universal prescriptions |
| What is the intended active ion? | Determines the drug-electrode polarity |
| Is the solution water-soluble and ionized? | Strongly influences iontophoretic transport |
| Is the formulation compatible with the reservoir? | Some patches have specific volume, pH and polarity requirements |
| Is the selected patch limited to negative medication? | Not every wearable patch accepts both polarities |
| Is the medication included in the device labeling? | Device and medication requirements must be checked separately |
| Does the patient have a medication contraindication or allergy? | Transdermal administration does not eliminate drug risk |
| Is the skin intact and appropriate for treatment? | Skin damage can alter current density and absorption |
| Has the pharmacist confirmed the formulation? | Pharmacy review helps prevent polarity and compatibility errors |
Documentation Checklist
For each treatment, consider documenting:
- Exact drug and salt form
- Concentration and volume
- Prescriber and order date
- Reported medication polarity
- Active-electrode polarity
- Electrode or patch brand and model
- Treatment site
- Programmed or patch dose in mA-min
- Current and time when a controller is used
- Skin condition before application
- Patient response during treatment
- Skin condition after removal
- Patient instructions and expected removal time
- Any adverse reaction or treatment interruption
For coding considerations, see our Iontophoresis Reimbursement Codes and Documentation Guide.
Frequently Asked Questions
What medications are most commonly associated with physical therapy iontophoresis?
Dexamethasone sodium phosphate is the medication most frequently discussed in contemporary physical therapy and sports medicine literature. Acetic acid, lidocaine, salicylates, and selected NSAIDs have also been investigated, but the quality and consistency of evidence vary.
Is dexamethasone positively or negatively charged?
Dexamethasone sodium phosphate is commonly treated as negatively charged and is generally placed beneath the negative drug electrode. Confirm the exact formulation and device instructions.
Is lidocaine positive or negative for iontophoresis?
Lidocaine hydrochloride is commonly treated as positively charged. Other lidocaine formulations should not automatically be assumed to have identical iontophoretic characteristics.
Is acetic acid positive or negative?
The acetate ion is negative and is generally delivered from the negative electrode.
Does acetic-acid iontophoresis dissolve calcium deposits?
That claim is not supported as a reliable general outcome. A randomized trial of calcific shoulder tendinopathy found no better clinical or radiographic results from acetic-acid iontophoresis plus physiotherapy than from physiotherapy alone. (ScienceDirect)
What is the best medication for iontophoresis?
There is no universal best medication. The selection depends on the diagnosis, evidence for that condition, the prescriber’s order, medication risks, polarity, formulation, device labeling, and patient-specific factors.
Can any water-soluble medication be used?
No. Water solubility alone does not establish suitable charge, stability, safety, tissue delivery, effectiveness, or device compatibility.
Can two drugs be mixed in one iontophoresis electrode?
Only when specifically prescribed, compounded, and confirmed compatible by qualified pharmacy and clinical personnel. Combining solutions can change pH, charge, stability, and the amount of each drug transported.
Is tap water iontophoresis drug delivery?
Not in the conventional sense. It is commonly used for hyperhidrosis without an added prescription drug. The electrical treatment and ions naturally present in the water contribute to the effect.
Is pilocarpine iontophoresis a physical-therapy treatment?
No. Quantitative pilocarpine iontophoresis is primarily a controlled diagnostic procedure used to stimulate sweat for cystic fibrosis testing.
Are the historical ions still used today?
Some appear mainly in older textbooks and case reports. Their presence in a historical chart does not mean they remain accepted, available, or appropriate for current practice.
Can chemotherapy drugs be delivered by iontophoresis?
Specialized studies have investigated cytotoxic substances, including an old report involving vincristine and vinblastine. These hazardous drugs should never be treated as ordinary rehabilitation additives or handled outside appropriate oncology, pharmacy, and research controls.
Does FDA clearance of an iontophoresis device approve the medication?
Not by itself. Device clearance and drug approval are distinct regulatory questions. The drug, formulation, device labeling, and intended use all require separate verification.
Where can I compare iontophoresis patches and electrodes?
Visit Balego’s iontophoresis collection or read the IontoPatch vs. ACTIVApatch comparison.
Selected Research References
- Transdermal iontophoresis: mechanisms and drug-delivery principles
- 2024 Clinical Practice Guideline for Midportion Achilles Tendinopathy
- Effects of current magnitude and duration on dexamethasone delivery
- Skin thickness, time and dexamethasone-phosphate absorption
- Acetic-acid iontophoresis for calcific shoulder tendinopathy: randomized trial
- Dexamethasone and acetic-acid iontophoresis for plantar fasciitis
- Lidocaine iontophoresis before intravenous cannulation
- Lidocaine iontophoresis before pediatric dermatologic procedures
- Cystic Fibrosis Foundation Sweat Test Guidelines
- Tap-water iontophoresis for palmar and plantar hyperhidrosis
- Sodium salicylate and sodium diclofenac iontophoresis for lateral epicondylitis
- Historical vincristine and vinblastine iontophoresis report
Medical and Regulatory Notice
This article is intended for healthcare professional education and literature review. It does not recommend or authorize the use of any medication, chemical, or solution with an iontophoresis product.
Use only:
- A valid medication order
- The exact prescribed formulation
- A compatible FDA-cleared device or electrode system
- The current manufacturer's Instructions for Use
- Applicable pharmacy and facility policies
- Appropriate patient screening and monitoring
Do not use this article as a compounding formula, dosing protocol, or substitute for medical, pharmaceutical, or regulatory guidance.
substances delivered by iontophoresis, iontophoresis medications, iontophoresis drug list, dexamethasone iontophoresis, iontophoresis polarity chart, drugs used in iontophoresis
